Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) trades at $0.84 with AI Score 52/100 (Grade B). Genomma Lab Internacional, S. A. B. Market cap: $818.18M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for GNMLF: GNMLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNMLF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GNMLF: 5/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Healthcare & Pipeline Overview
Genomma Lab Internacional, S.A.B. de C.V. specializes in the development and marketing of over-the-counter pharmaceutical and personal care products, leveraging a robust portfolio of well-known brands to capture market share in the healthcare sector.
What Is the Investment Thesis for GNMLF?
Genomma Lab Internacional, S.A.B. de C.V. presents a compelling investment thesis characterized by a market capitalization of $818.18M and a P/E ratio of 8.63, which indicates potential undervaluation compared to industry peers. The company boasts a gross margin of 62.7% and a profit margin of 9.6%, reflecting strong operational efficiency. Key growth catalysts include the expansion of its product portfolio and geographic reach, particularly in emerging markets, where demand for over-the-counter health products is on the rise. The company’s dividend yield of 5.46% further enhances its attractiveness to income-focused investors. However, potential risks include market competition and regulatory challenges in the healthcare sector, which could impact profitability and growth trajectories.
Based on FMP financials and quantitative analysis
GNMLF Key Highlights
- Market Cap of $818.18M indicates a strong market presence in the healthcare sector.
- P/E ratio of 8.63 suggests potential undervaluation relative to peers.
- Gross margin of 62.7% demonstrates strong operational efficiency.
- Profit margin of 9.6% reflects effective cost management.
- Dividend yield of 5.46% offers attractive returns for income-focused investors.
Who Are GNMLF's Competitors?
GNMLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PFE Pfizer Inc. | $23.73 | -2.43% | $135.25B | 64 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNMLF's Key Strengths?
- Strong market presence in the OTC pharmaceutical sector.
- Diverse product portfolio with well-known brands.
- Effective cost management leading to healthy profit margins.
What Are GNMLF's Weaknesses?
- Dependence on the Mexican market for a significant portion of revenue.
- Limited presence in certain international markets compared to competitors.
- Potential vulnerabilities to regulatory changes in the healthcare sector.
What Could Drive GNMLF Stock Higher?
- Expansion of product lines into new therapeutic areas to capture additional market share.
- Strong brand recognition driving consumer loyalty and repeat purchases.
- Strategic partnerships enhancing distribution capabilities and market reach.
What Are the Key Risks for GNMLF?
- Regulatory changes that could impact product approvals and market access.
- Intense competition from both established and emerging players in the healthcare sector.
- Economic downturns affecting consumer spending on healthcare products.
What Are the Growth Opportunities for GNMLF?
- Expansion into Emerging Markets: Genomma Lab has significant growth potential in emerging markets, particularly in Latin America and Asia, where the demand for over-the-counter pharmaceutical products is rising. The global OTC market is projected to grow at a CAGR of 5.5%, providing Genomma Lab with opportunities to increase its market share and revenue in these regions over the next five years.
- Product Line Diversification: The company can enhance its product offerings by developing new formulations and entering additional therapeutic areas. With a focus on health and wellness, Genomma Lab can tap into the growing consumer trend towards preventive healthcare, potentially increasing its revenue streams and brand loyalty.
- Digital Marketing and E-commerce Growth: As consumer purchasing habits shift towards online platforms, Genomma Lab can leverage digital marketing strategies to enhance brand visibility and drive e-commerce sales. This transition could lead to a significant increase in market penetration and customer engagement, particularly among younger demographics.
- Strategic Partnerships and Collaborations: Forming strategic alliances with healthcare providers and distributors can enhance Genomma Lab’s market reach and distribution capabilities. Collaborations with other companies in the healthcare sector can also facilitate innovation and expedite product development, positioning the company for sustained growth.
- Sustainability Initiatives: By investing in sustainable practices and eco-friendly product lines, Genomma Lab can appeal to environmentally conscious consumers. This focus on sustainability can enhance brand reputation and open up new market opportunities, particularly among consumers prioritizing health and environmental impact.
What Opportunities Does GNMLF Have?
- Expansion into high-growth emerging markets.
- Increasing consumer demand for health and wellness products.
- Potential for product line diversification and innovation.
What Threats Does GNMLF Face?
- Intense competition from both established and new entrants.
- Regulatory challenges that could impact product approvals.
- Economic fluctuations affecting consumer spending on healthcare.
What Are GNMLF's Competitive Advantages?
- Strong brand recognition with established product lines.
- Robust distribution network in domestic and international markets.
- Diverse product offerings catering to various health and wellness needs.
What Does GNMLF Do?
Genomma Lab Internacional, S.A.B. de C.V. was established in 1996 and is headquartered in Mexico City, Mexico. The company has evolved into a prominent player in the healthcare sector, focusing on the development, marketing, and sale of a wide variety of over-the-counter pharmaceutical and personal care products. Genomma Lab’s product offerings include skin care, health and wellness, hair care, pain relief, cough and cold remedies, gastro health, sexual health, antiperspirant deodorants, hand sanitizers, and razors. The company is also involved in the production of analgesics, antifungals, and hemorrhoid treatments. It markets its products under several well-recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, and Tío Nacho, among others. With a workforce of approximately 1,605 employees, Genomma Lab has established a significant presence not only in Mexico but also in international markets, expanding its reach to various countries. The company’s commitment to innovation and quality has positioned it favorably in a competitive landscape, allowing it to cater to the diverse health and wellness needs of consumers globally.
What Products and Services Does GNMLF Offer?
- Develops and markets over-the-counter pharmaceutical products.
- Offers a diverse range of personal care products.
- Focuses on health and wellness solutions.
- Provides products in categories like skin care, hair care, and pain relief.
- Operates under well-known brands recognized in various markets.
- Engages in international sales and marketing efforts.
How Does GNMLF Make Money?
- Generates revenue through the sale of over-the-counter pharmaceutical products.
- Markets personal care items across multiple categories.
- Utilizes a strong brand portfolio to enhance consumer recognition and loyalty.
What Industry Does GNMLF Operate In?
The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing robust growth driven by increasing consumer demand for over-the-counter health products. The global market for over-the-counter drugs is expected to reach approximately $200 billion by 2026, with a compound annual growth rate (CAGR) of around 5.5%. Genomma Lab Internacional, S.A.B. de C.V. operates in a competitive landscape that includes both established players and emerging companies. Its diverse product range and strong brand recognition position it favorably to capitalize on market trends, particularly in Latin America, where healthcare spending is increasing.
Who Are GNMLF's Key Customers?
- Targets consumers seeking over-the-counter health solutions.
- Caters to a diverse demographic across various age groups.
- Serves both domestic and international markets.
Company Profile
Genomma Lab Internacional, S.A.B. de C.V. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Mexico City, MX. The company is led by CEO Juan Marco Sparvieri. GNMLF has traded publicly since 2012.
How Genomma Lab Internacional, S.A.B. de C.V. Is Valued
Genomma Lab Internacional, S.A.B. de C.V. carries a market capitalization of $818.18M, placing it in the small-cap category. Relative to its peer group, GNMLF's quantitative score of 52/100 is below the peer average of 76/100.
ROE 15%Key Financial Metrics
Return on equity for Genomma Lab Internacional, S.A.B. de C.V. stands at 14.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.7%, showing how much profit it generates from its asset base. GNMLF trades at a trailing price-to-earnings ratio of 8.58, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 11.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Genomma Lab Internacional, S.A.B. de C.V.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.50 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Genomma Lab Internacional, S.A.B. de C.V. revenue of about $18.60B for fiscal 2026, with EPS near $2.13. The estimate reflects 5 contributing analysts.
GNMLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future performance, indicating that executives believe in the growth potential.
- Community sentiment has shifted positively, with discussions highlighting new product launches that could drive revenue.
- Analysts are noting improvements in operational efficiency, which may enhance profitability moving forward.
- Increased market presence in emerging markets is generating excitement among investors, positioning the company for future growth.
Bear Case
- Concerns over rising competition in the consumer health sector are causing some investors to reevaluate their positions.
- Recent community discussions have raised red flags about supply chain issues that could impact product availability.
- Market perception remains cautious due to previous underperformance in key segments, leading to skepticism about recovery.
- Insider selling activity has been observed, which may indicate a lack of confidence in the short-term outlook for the company.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNMLF Latest News
No recent news available for GNMLF.
GNMLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNMLF.
Price Targets
Wall Street price target analysis for GNMLF.
GNMLF MoonshotScore
What does this score mean?
The MoonshotScore rates GNMLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Juan Marco Sparvieri
CEO
Juan Marco Sparvieri has extensive experience in the healthcare and consumer goods sectors, having held various leadership positions prior to becoming CEO of Genomma Lab Internacional. He holds a degree in Business Administration and has a strong track record in driving growth and operational efficiency within organizations. His leadership style emphasizes innovation and strategic partnerships.
Track Record: Under Juan Marco Sparvieri's leadership, Genomma Lab has expanded its product portfolio and strengthened its market position in Latin America. His strategic focus on brand development and market penetration has resulted in significant revenue growth and improved operational performance.
GNMLF OTC Market Information
The OTC Other tier is a classification for companies that trade on the over-the-counter market, typically characterized by less stringent reporting requirements compared to NYSE or NASDAQ. This tier allows companies to access capital markets while maintaining flexibility in their operations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight compared to major exchanges, which may impact transparency.
- Potential for lower liquidity, leading to higher volatility in stock prices.
- Increased risk of fraud or misrepresentation in OTC markets.
- Verify financial statements and earnings reports for accuracy.
- Assess the company's market position and competitive landscape.
- Evaluate management's track record and strategic vision.
- Investigate any regulatory or legal issues affecting the company.
- Review analyst reports and market sentiment regarding the stock.
- Established brand presence in the healthcare market.
- Consistent revenue growth and profitability metrics.
- Transparency in communications and disclosures.
Common Questions About GNMLF (Healthcare)
What does Genomma Lab Internacional, S.A.B. de C.V. do?
Genomma Lab Internacional, S.A.B. de C.V. develops and markets a wide range of over-the-counter pharmaceutical and personal care products. The company focuses on health and wellness, offering products in categories such as skin care, hair care, pain relief, and cough and cold remedies. Its extensive brand portfolio includes well-known names like Cicatricure and Tío Nacho, catering to both domestic and international markets.
What are the key growth opportunities for GNMLF in healthcare?
Genomma Lab Internacional, S.A.B. de C.V. has several key growth opportunities, including expansion into emerging markets where demand for OTC products is increasing. The company can also diversify its product lines to address new therapeutic areas, tapping into the growing consumer trend towards preventive healthcare. Additionally, leveraging digital marketing and e-commerce can enhance brand visibility and drive sales.
What are the main risks for GNMLF?
Genomma Lab Internacional, S.A.B. de C.V. faces several risks, including intense competition from both established and new entrants in the healthcare market. Regulatory challenges may impact product approvals and market access, while economic fluctuations could affect consumer spending on healthcare products. Additionally, dependence on the Mexican market for revenue poses risks if local economic conditions change.
What are the key factors to evaluate for GNMLF?
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does GNMLF data refresh on this page?
GNMLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNMLF's recent stock price performance?
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in the OTC pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNMLF overvalued or undervalued right now?
Valuing Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNMLF?
Before investing in Genomma Lab Internacional, S.A.B. de C.V. (GNMLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The financial reports and disclosures may vary in availability and transparency due to OTC classification.